Chemical: Drug
bumetanide

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for bumetanide

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs11966370 NC_000006.11:g.25850171G>A, NC_000006.12:g.25849943G>A, NG_032922.1:g.29301C>T, NM_001098486.1:c.1133C>T, NM_006632.3:c.899C>T, NP_001091956.1:p.Pro378Leu, NP_006623.2:p.Pro300Leu, XM_005248819.1:c.506C>T, XP_005248876.1:p.Pro169Leu
G > A
SNP
P378L
No VIP available CA VA
rs1529927 NC_000016.10:g.56870675C>G, NC_000016.9:g.56904587C>G, NG_009386.1:g.10469G=, NG_009386.1:g.10469G>C, NM_000339.2:c.791G=, NM_000339.2:c.791G>C, NM_001126107.1:c.788G=, NM_001126107.1:c.788G>C, NM_001126108.1:c.791G=, NM_001126108.1:c.791G>C, NP_000330.2:p.Gly264=, NP_000330.2:p.Gly264Ala, NP_001119579.1:p.Gly263=, NP_001119579.1:p.Gly263Ala, NP_001119580.1:p.Gly264=, NP_001119580.1:p.Gly264Ala, XM_005256119.1:c.788C>G, XP_005256176.1:p.Ala263Gly, rs52815294
C > G
SNP
G264A
No VIP available CA VA
rs1799752 NC_000017.10:g.61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.10:g.61565890_61565891insG, NC_000017.11:g.63488529_63488530insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.11:g.63488529_63488530insG, NG_011648.1:g.16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NG_011648.1:g.16457_16458insG, NM_000789.3:c.2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_000789.3:c.2306-119_2306-118insG, NM_001178057.1:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_001178057.1:c.584-119_584-118insG, NM_152830.2:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_152830.2:c.584-119_584-118insG, XM_005257110.1:c.1757-119_1757-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_005257110.1:c.1757-119_1757-118insG, XM_006721737.2:c.644-119_644-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_006721737.2:c.644-119_644-118insG
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
- > G
indel
No VIP available No Clinical Annotations available VA
rs34376145 NC_000006.11:g.25851049C>A, NC_000006.12:g.25850821C>A, NG_032922.1:g.28423G>T, NM_001098486.1:c.769G>T, NM_006632.3:c.535G>T, NP_001091956.1:p.Val257Phe, NP_006623.2:p.Val179Phe, XM_005248819.1:c.142G>T, XP_005248876.1:p.Val48Phe
C > A
SNP
V257F
No VIP available No Clinical Annotations available VA
rs34902660 NC_000006.11:g.25851102C>A, NC_000006.12:g.25850874C>A, NG_032922.1:g.28370G>T, NM_001098486.1:c.716G>T, NM_006632.3:c.482G>T, NP_001091956.1:p.Gly239Val, NP_006623.2:p.Gly161Val, XM_005248819.1:c.89G>T, XP_005248876.1:p.Gly30Val
C > A
SNP
G239V
No VIP available CA VA
rs4961 NC_000004.11:g.2906707G>T, NC_000004.12:g.2904980G>T, NG_012037.1:g.66124G>T, NM_001119.4:c.1378G>T, NM_001286645.1:c.1378G>T, NM_014189.3:c.1378G>T, NM_014190.3:c.1378G>T, NM_176801.2:c.1378G>T, NP_001110.2:p.Gly460Trp, NP_001273574.1:p.Gly460Trp, NP_054908.2:p.Gly460Trp, NP_054909.2:p.Gly460Trp, NP_789771.1:p.Gly460Trp, XM_005247933.1:c.1378G>T, XM_005247934.1:c.1378G>T, XM_005247935.1:c.1378G>T, XM_005247936.1:c.1378G>T, XM_005247937.1:c.1378G>T, XM_005247938.1:c.1378G>T, XP_005247990.1:p.Gly460Trp, XP_005247991.1:p.Gly460Trp, XP_005247992.1:p.Gly460Trp, XP_005247993.1:p.Gly460Trp, XP_005247994.1:p.Gly460Trp, XP_005247995.1:p.Gly460Trp, rs113752720, rs52823896, rs61347248
G > T
SNP
G460W
No VIP available CA VA
rs5063 NC_000001.10:g.11907648C>T, NC_000001.11:g.11847591C>T, NG_012926.1:g.5193G>A, NM_006172.3:c.94G>A, NP_006163.1:p.Val32Met, NR_037806.1:n.1637C>T, rs118109392, rs386597503, rs56762574
C > -
C > A
SNP
V32M
No VIP available No Clinical Annotations available VA
rs5065 NC_000001.10:g.11906068A>G, NC_000001.11:g.11846011A>G, NG_012926.1:g.6773T>C, NM_006172.3:c.454T>C, NP_006163.1:p.Ter152Arg, NR_037806.1:n.1479+245A>G, rs1130764, rs17413194, rs17856153, rs198363, rs3189984, rs57081035
A > G
SNP
*152R
No VIP available CA VA
rs5443 NC_000012.11:g.6954875C>T, NC_000012.12:g.6845711C>T, NG_009100.1:g.10501C>T, NM_001297571.1:c.822C>T, NM_002075.3:c.825C>T, NP_001284500.1:p.Ser274=, NP_002066.1:p.Ser275=, NW_003871083.2:g.47295C>T, XM_005253679.1:c.825C>T, XM_005253680.1:c.822C>T, XM_005253681.1:c.702-6C>T, XM_005277751.1:c.825C>T, XM_005277752.1:c.822C>T, XM_005277753.1:c.702-6C>T, XM_011520953.1:c.825C>T, XM_011520954.1:c.822C>T, XM_011521027.1:c.*1818G>A, XM_011521028.1:c.*1818G>A, XM_011521029.1:c.*2036G>A, XM_011521030.1:c.*1969G>A, XP_005253736.1:p.Ser275=, XP_005253737.1:p.Ser274=, XP_005277808.1:p.Ser275=, XP_005277809.1:p.Ser274=, XP_011519255.1:p.Ser275=, XP_011519256.1:p.Ser274=, rs2230334, rs3138516, rs57419337, rs6489738
C > T
SNP
S274S
No VIP available No Clinical Annotations available VA
rs56027330 NC_000006.11:g.25850845C>T, NC_000006.12:g.25850617C>T, NG_032922.1:g.28627G>A, NM_001098486.1:c.835G>A, NM_006632.3:c.601G>A, NP_001091956.1:p.Gly279Arg, NP_006623.2:p.Gly201Arg, XM_005248819.1:c.208G>A, XP_005248876.1:p.Gly70Arg, rs61745238
C > T
SNP
G279R
No VIP available No Clinical Annotations available VA
rs5723 NC_000016.10:g.23215466C>G, NC_000016.9:g.23226787C>G, NG_011909.1:g.37748C>G, NM_001039.3:c.1947C>G, NP_001030.2:p.Leu649=, XM_005255468.1:c.1947C>G, XM_005255469.1:c.1848C>G, XP_005255525.1:p.Leu649=, XP_005255526.1:p.Leu616=, rs2228992, rs57201603
C > G
SNP
L649L
No VIP available No Clinical Annotations available VA
rs5729 NC_000016.10:g.23216075T>A, NC_000016.9:g.23227396T>A, NG_011909.1:g.38357T>A, NM_001039.3:c.*606T>A, XM_005255468.1:c.*606T>A, XM_005255469.1:c.*606T>A, rs60508947
T > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Bumetanida [INN-Spanish]
  • Bumetanidum [INN-Latin]
Trade Names
  • Bumex
  • Burine
  • Burinex
  • Fontego
  • Fordiuran
  • Lixil
  • Lunetoron
  • Segurex
Brand Mixture Names

PharmGKB Accession Id

PA448682

Type(s):

Drug

Description

A sulfamyl diuretic.

Source: Drug Bank

Indication

For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.

Source: Drug Bank

Pharmacology

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

Source: Drug Bank

Food Interaction

Take with food to reduce irritation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.

Source: Drug Bank

Protein Binding

97%

Source: Drug Bank

Absorption

Bumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.

Source: Drug Bank

Half-Life

60-90 minutes

Source: Drug Bank

Toxicity

Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.

Source: Drug Bank

Chemical Properties

Chemical Formula

C17H20N2O5S

Source: Drug Bank

Isomeric SMILES

CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O

Source: OpenEye

Canonical SMILES

CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O

Source: Drug Bank

Average Molecular Weight

364.416

Source: Drug Bank

Monoisotopic Molecular Weight

364.10929245

Source: Drug Bank

SMILES

CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O

Source: Drug Bank

InChI String

InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
CFTR (source: Drug Bank )
SLC12A1 (source: Drug Bank )
SLC12A2 (source: Drug Bank )
SLC12A4 (source: Drug Bank )
SLC12A5 (source: Drug Bank )

Drug Interactions

Interaction Description
amikacin - bumetanide Increased ototoxicity (source: Drug Bank )
bumetanide - amikacin Increased ototoxicity (source: Drug Bank )
bumetanide - cisplatin Increased ototoxicity (source: Drug Bank )
bumetanide - cisplatin Increased ototoxicity (source: Drug Bank )
bumetanide - deslanoside Possible electrolyte variations and arrhythmias (source: Drug Bank )
bumetanide - digitoxin Possible electrolyte variations and arrhythmias (source: Drug Bank )
bumetanide - digitoxin Possible electrolyte variations and arrhythmias (source: Drug Bank )
bumetanide - digoxin Possible electrolyte variations and arrhythmias (source: Drug Bank )
bumetanide - digoxin Possible electrolyte variations and arrhythmias (source: Drug Bank )
bumetanide - gentamicin Increased ototoxicity (source: Drug Bank )
bumetanide - gentamicin Increased ototoxicity (source: Drug Bank )
bumetanide - ginseng Ginseng decreases the therapeutic effect of diuretic (source: Drug Bank )
bumetanide - ibuprofen The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank )
bumetanide - ibuprofen The NSAID, ibuprofen, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide. (source: Drug Bank )
bumetanide - indomethacin The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank )
bumetanide - indomethacin The NSAID, indomethacin, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide. (source: Drug Bank )
bumetanide - kanamycin Increased ototoxicity (source: Drug Bank )
bumetanide - kanamycin Increased ototoxicity (source: Drug Bank )
bumetanide - netilmicin Increased ototoxicity (source: Drug Bank )
bumetanide - streptomycin Increased ototoxicity (source: Drug Bank )
bumetanide - streptomycin Increased ototoxicity (source: Drug Bank )
bumetanide - sulindac The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank )
bumetanide - sulindac The NSAID, sulindac, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide. (source: Drug Bank )
bumetanide - tobramycin Increased ototoxicity (source: Drug Bank )
bumetanide - tobramycin Increased ototoxicity (source: Drug Bank )
digoxin - bumetanide Possible electrolyte variations and arrhythmias (source: Drug Bank )
digoxin - bumetanide Possible electrolyte variations and arrhythmias (source: Drug Bank )
gentamicin - bumetanide Increased ototoxicity (source: Drug Bank )
gentamicin - bumetanide Increased ototoxicity (source: Drug Bank )
ibuprofen - bumetanide The NSAID decreases the diuretic and antihypertensive effect of the loop diuretic (source: Drug Bank )
ibuprofen - bumetanide The NSAID, ibuprofen, may decrease the diuretic and antihypertensive effect of the loop diuretic, bumetanide. (source: Drug Bank )
indomethacin - bumetanide The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank )
indomethacin - bumetanide The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide. (source: Drug Bank )
netilmicin - bumetanide Increased ototoxicity (source: Drug Bank )
trandolapril - bumetanide The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril. (source: Drug Bank )
treprostinil - bumetanide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank )

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to bumetanide: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms. Journal of pharmacological sciences. 2011. Jutabha Promsuk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The genetics of loop diuretic effects. The pharmacogenomics journal. 2010. Vormfelde S V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clinical pharmacology and therapeutics. 2007. Vormfelde S V, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0004-0125-01
DrugBank:
DB00887
ChEBI:
3213
KEGG Drug:
D00247
PubChem Compound:
2471
PubChem Substance:
175984
46508147
Drugs Product Database (DPD):
728284
BindingDB:
25903
ChemSpider:
2377
Therapeutic Targets Database:
DAP000361
FDA Drug Label at DailyMed:
a4987159-7590-47a6-be10-b50557c30fab

Clinical Trials

These are trials that mention bumetanide and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.